Modified radical mastectomy is associated with a relatively high incidence of postoperative nausea and vomiting (PONV). This study was undertaken to evaluate the comparative profile and efficacy of ondansetron and granisetron to prevent PONV after modified radical mastectomy. In a randomized, double-blind, placebo-controlled trial, sixty female patients received ondansetron 4 mg, granisetron 1 mg or saline intravenously just before induction of anaesthesia (n=20 for each group). A standardized general anaesthetic technique was employed. The incidence of PONV and adverse events were recorded for the first 24 h postoperatively. The incidence of PONV was 25% with ondansetron, 20% with granisetron and 70% with saline (P<0.05, Chi-square test with Yates' correction factor). The incidence of adverse events was comparable among the groups. Ondansetron and granisetron are both effective for reducing the incidence of PONV in female patients undergoing modified radical mastectomy.
Postoperative nausea and vomiting (PONV) are frequent and distressing adverse events after surgery performed under general anaesthesia, with female patients being particularly susceptible 1 . The overall incidence of PONV after general anaesthesia is approximately 20% 2 . Breast surgery performed with general anaesthesia has been found to have a very high incidence of PONV (60%-84%) [3] [4] [5] [6] [7] [8] . Ondansetron and granisetron, selective 5-HT3 receptor antagonists reduce the incidence of PONV after breast surgery 9, 10 . Studies have shown that granisetron (in contrast to ondansetron) produces irreversible block of 5HT3 receptor 11, 12 which may account for its longer duration of action. Furthermore, in studies comparing the potency of different 5-HT3 receptor antagonists, granisetron has been shown to have a greater potency than ondansetron 13 .
To our knowledge there have been no previous studies comparing the efficacy of granisetron with that of the more commonly used ondansetron follow-ing modified radical mastectomy. In the present study we conducted a randomized, double-blind, placebocontrolled trial to evaluate the efficacy and comparative profile of granisetron and ondansetron for preventing PONV in patients undergoing breast surgery.
MATERIAL AND METHODS
After Institutional Ethics Committee approval and informed consent, we studied sixty American Society of Anesthesiologists physical status 1 or 2 patients between the ages of 21 and 75 years, undergoing general anaesthesia for modified radical mastectomy. The study was conducted for a limited duration of six months in which the total of 60 cases were randomly divided into three groups. Group 1 received ondansetron 4 mg, group 2 received granisetron 1 mg, and group 3 received saline.
Patients with known stomach disorders, history of heart burn, motion sickness, previous PONV, lower oesophageal sphincter disorders, menstruation, uncontrolled hypertension, poorly controlled diabetics, or preoperative emesis less than 12 h prior to surgery were excluded from the study.
Patients were randomly allocated to receive one of three treatments in the same volume (i.e. 10 ml) administered intravenously just before induction. Randomization was achieved using a computer-generated random number list to assign patients into three equal groups (n=20). Anaesthetists were blinded to the group to which the patients had been assigned.
All patients were premedicated with intramuscular injection of fentanyl 2 µg/kg and glycopyrrolate 0.1 mg 30 minutes before surgery. The patients received diazepam 0.1 mg/kg orally on the night before surgery. Anaesthesia was induced with thiopentone sodium 2.5% 4-6 mg/kg. Tracheal intubation was facilitated with vecuronium 0.1 mg/kg. After tracheal intubation, anaesthesia was maintained with 66% nitrous oxide and 1 to 3% (inspired concentration) isoflurane in oxygen. We adjusted the isoflurane concentration to maintain blood pressure and heart rate within 15% of preinduction values. Ventilation was mechanically controlled and was adjusted to keep the end-tidal CO 2 between 35 and 45 mmHg. Before tracheal extubation, a nasogastric tube was inserted and suction was applied to empty the contents of the stomach. At the cessation of the surgical procedure, nitrous oxide and isoflurane administration were ceased. Residual neuromuscular blockade was antagonized with neostigmine 50 to 70 µg/kg with glycopyrrolate 8 to 10 µg/kg, and the trachea was extubated when the patient was awake. All patients received intramuscular injection of diclofenac sodium 75 mg for postoperative pain relief. Postoperatively, all episodes of PONV were recorded for the first 24 hours (0-2, 2-6, 6-24 hours) by direct questioning by the attending anaesthetist or by spontaneous complaint by the patients.
All patients were evaluated by using a PONV numeric scoring system. 0=No nausea/vomiting 1=Nausea alone 2=Vomiting once 3=Vomiting twice or more times in 30 minute interval. A rescue antiemetic, ondansetron 4 mg intravenously, was given to all patients with PONV score =3.
Statistical analysis of data between the groups was performed using one-way analysis of variance (ANOVA). For the categorical data, Chi-square test with Yates' correction factor was applied. A "P" value less than 0.05 was considered as statistically significant. All values were expressed as mean (standard deviation) or number or percentage.
RESULTS
There were no significant differences between the groups with regard to age, weight, ASA physical status, duration of anaesthesia, or intraoperative or postoperative analgesic requirements (Table 1) .
During the first 24 h, the number of patients who vomited twice or more within a 30 minute interval (PONV=3) was 5 in the ondansetron group, 4 in the granisetron group and 14 in the saline group respectively. Vomiting once only (PONV=2) was present in one patient in the ondansetron group, no patients in the granisetron group, and 3 patients in the saline group. Nausea only (PONV=1) was present in 2 patients in the ondansetron group, one in the granisetron group, and 3 in the saline group respectively. The incidence of PONV=3 in patients who had received granisetron and ondansetron was lower than that in those who received saline (P=0.0016). This difference was statistically significant for both the two to six hour interval and overall (0 to 24 hours) ( Table  2 ). However, there was no statistically significant difference in the incidence of PONV scores 1 or 2 between the groups.
Rescue antiemetic was required in 4 patients in the ondansetron group, 3 patients from the granisetron group and 8 patients from the saline group, while one out of 8 patients in the saline group required repeat dose of rescue antiemetic drug. No difference in the incidence of other adverse effects was observed among the groups.
DISCUSSION
The aetiology of PONV following breast surgery performed under general anaesthesia is complex and is dependent on a variety of factors which include age, gender, obesity, history of mountain sickness or previous PONV, phase of menstrual cycle, operative procedure, anaesthetic and analgesic technique and postoperative pain. In this study, the treatment groups were similar in regard to patient demographics, surgical procedure, anaesthetic administered and analgesic used postoperatively. Despite this, the saline group had an incidence of PONV=3 of 70%, compared to 25% in the ondansetron group and 20% in the granisetron group. The incidence of nausea only (PONV=1), and vomiting once (PONV=2), appeared to be higher in saline group but the differences were not statistically significant. The difference in the incidence between the groups is likely to be due to the antiemetics administered. We cannot exclude a difference in the antiemetic efficacy of the two drugs for severe PONV due to the small sample size. For the same reason, we cannot comment on their effect on mild PONV.
The incidence and severity of PONV in our study is comparable to previous studies, which have shown incidence of PONV in the range of 60 to 84% after breast surgery [3] [4] [5] [6] [7] [8] . Fujii et al demonstrated 18% PONV after breast surgery after granisetron, which is similar to our study 19 . One previous study by Senthil et al had shown slightly higher incidence (33%) of PONV in patients receiving ondansetron 7 .
The complex act of vomiting involves coordination of the respiratory, gastrointestinal, and abdominal musculature and is controlled by the emetic centre, which is considered to be situated in the lateral reticular formation close to the tractus solitarius in the brainstem 1, 14 . Stimuli from several areas within the central nervous system can affect the emetic centre. These include afferents from the pharynx, gastrointestinal tract and mediastinum, as well as afferents from the higher cortical centres (including the visual centre and the vestibular portion of the eighth cranial nerve) and the chemoreceptor trigger zone in the area prostrema. The area prostrema of the brain is rich in dopamine, opioid, serotonin and 5-hydroxytryptamine (5-HT3) receptors 1 .
Four major neurotransmitter systems appears to play important roles in mediating the emetic response viz. dopaminergic, histaminic (H1), cholinergic, and 5-HT3 1 . As there are four different types of receptors, there are at least four sites of action of the antiemetic drugs. Antiemetic agents may have actions at more than one receptor but they tend to have a more prominent action at one or two receptors 1, 14 . In current practice the 5-HT3 receptor antagonists have been used because of lack of side-effects such as sedation and extra pyramidal reactions. 5-HT3 receptor antagonists include ondansetron, granisetron, dolansetron and tropisetron. All 5-HT3 receptor antagonists have the same basic double nitrogen ring backbone for their chemical structure. This may be the chemical site of action of the 5-HT3 receptor antagonists 15 . 5-HT3 receptor antagonists are often used in current practice to reduce PONV following modified radical mastectomy surgery.
Granisetron and ondansetron have been proved to be effective in the reduction of emesis induced by cancer chemotherapy 16 , while Fujii et al have demonstrated that it also has a potent antiemetic effect on PONV after breast surgery 17 . Wilson et al compared different doses of intravenous granisetron in the prevention of PONV and found the optimal dose was 1 mg; therefore this dose was used in our study 18 . Our results show that the incidence of severe PONV in patients who had received ondansetron or granisetron was less than those who had received placebo (P<0.05). These findings suggest that ondansetron and granisetron are effective in reducing PONV after breast surgery.
The adverse effects observed in this study were relatively mild, and there was no difference in the incidence of headache, dizziness, anxiety, insomnia, which was comparable with other studies.
In conclusion, both ondansetron and granisetron appear to be effective in reducing the incidence of severe PONV in female patients undergoing modified radical mastectomy. However, we cannot exclude a difference in the antiemetic efficacy between the two drugs or comment on their effect on mild PONV, due to the small sample size.
